Evaxion to present new EVX-04 AML vaccine target data at ASH 2026

Evaxion A/S (NASDAQ: EVAX) said on November 4, 2026 that it will present new target validation data for EVX-04, an investigational off-the-shelf therapeutic vaccine for acute myeloid leukemia (AML), at the American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans, Louisiana, held December 12-15, 2026.

According to the company, the new data show broad patient coverage, conserved target expression across disease stages, and the induction of ERV-specific T-cell responses in humanized mice, supporting EVX-04's potential as an off-the-shelf vaccine for AML.¹ Evaxion said these findings build on data shown at the 2025 ASH meeting, where preclinical results demonstrated strong EVX-04-specific T-cell responses and tumor growth inhibition in mouse models.¹

The poster, titled "Validation of conserved ERV targets encoded by the off-the-shelf EVX-04 DNA vaccine for AML," is numbered 4310 and will be shown in Session 801, Gene Therapies: Poster II, at the Ernest N. Morial Convention Center, Hall F, on Sunday, December 13, 2026, from 6:00 to 8:00 pm ET.¹ The presenter is Daniela Kleine-Kohlbrecher, Director, Immuno-oncology, at Evaxion.¹

Evaxion describes EVX-04 as designed using its AI-Immunology platform to target non-conventional endogenous retrovirus (ERV) tumor antigens from the dark genome, which are selectively expressed in specific tumors but absent in normal tissue.¹ The company said its platform used sequencing data from AML patients to identify ERV tumor antigens, then mined roughly five million ERV antigen fragments to select 16 optimal fragment sets based on cross-patient relevance and immunogenic potential.¹ Evaxion said all 16 ERV fragments in EVX-04 elicited a specific immune response and prevented tumor growth in preclinical tumor models.¹ The vaccine is intended to be pre-produced and ready for immediate administration after diagnosis.¹